NCT05280626 2022-03-15
First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2 Not yet recruiting
Clinical Trials
7 trialsNCT05008666 2021-08-17
Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH
Sun Yat-sen University
Phase 2 Unknown
NCT04052659 2021-03-09
Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCL
Peking University
Phase 2 Unknown
NCT04676789 2020-12-21
SPENT
Sun Yat-sen University
Phase 2 Unknown
NCT04659434 2020-12-09
Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT04279379 2020-05-07
Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma
Beijing Tongren Hospital
Phase 2 Unknown
NCT04296786 2020-03-05
Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study
Peking Union Medical College Hospital
Phase 2 Unknown